Article Sidebar
DOI:
10.4314/tjpr.v14i6.6Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of Cytotoxicity of Pegylated Liposomal Recombinant Human Erythropoietin-alfa on Neuroblastoma Cell Line SHSY5Y
Abstract
Purpose: To evaluate the cytotoxic effect of pegylated liposomal Recombinant Human Erythropoietinalfa (rHuEPO) nanoparticles synthesized by reverse phase evaporation technique on SH-SY5Y cell line.
Methods: To prepare the nanoparticles of the drug, rHuEPO, PEG3000, cholesterol and
phosphatidylcholine were dissolved in buffer phosphate. The characteristics of the synthesized nanoparticles were determined by a zetasizer. Encapsulation efficiency, drug loading efficiency and drug release pattern were evaluated spectrophotometrically. The cytotoxicity effect of pegylated nanoliposomal rHuEPO was evaluated on SH-SY5Y cell line by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay.
Results: Size and zeta potential of pegylated nanoliposomal drug and blank pegylated nanoliposomes were 571 ± 6.8 nm, -16.5 mV; 280 ± 4.71 nm and -27.1 mV, respectively. Encapsulation and drug loading efficiency were 89 ± 3.9 % and 0.8 ± 0.012 %, respectively. Drug release data indicate that 17 % of rHuEPO was released from pegylated liposomal nanoparticles over a period of 30 h. The difference in cytotoxicity between the free drug (IC50 = 110.1 ± 3.1 μg/ml) and nanodrug (IC50 = 87.2 ± 2.3 μg/ml) was statistically significant (p ˂ 0.05).
Conclusion: This study shows that pegylated nanoliposomal rHuEPO has a powerful cytotoxic effect on SH-SY5Y cell line and is therefore a suitable alternative to the standard therapy, rHuEPO, for the chemotherapy of neuroblastoma.
Keywords: Recombinant Human Erythropoietin-alfa, Cytotoxicity, Drug delivery, Liposome, Reverse phase evaporation, SH-SY5Y cell line
